Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: Phase I study results.

CONCLUSIONS: Panobinostat with "7+3" for older AML patients was well tolerated. Panobinostat 50 mg on days 1, 3, 5, and 8 starting 2 days prior to "7+3" is recommended for future studies. Panobinostat-induced increases in histone acetylation in peripheral blood mononuclear cells predicted CR/CRi.
PMID: 31152020 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 30, 2019 Category: Cancer & Oncology Authors: Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KM, Anderson K, Munster PN, Andreadis C Tags: Clin Cancer Res Source Type: research